About EntreMed (NASDAQ:CASI)
CASI Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of therapeutics addressing cancer and other unmet medical needs in China. Its lead drug candidate is ENMD-2076, an Aurora A/angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma, triple-negative breast cancer, advanced ovarian clear cell carcinomas, and advanced/metastatic soft tissue sarcoma. The company's late-stage clinical drug candidates, including MARQIBO, a microtubule inhibitor to treat adult patients with philadelphia chromosome-negative acute lymphoblastic leukemia; ZEVALIN injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-hodgkin's lymphoma, as well as for the treatment of patients with previously untreated follicular non-hodgkin's lymphoma; and EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. In addition, its pipeline includes 2ME2 (2-methoxyestradial), an orally active compound that has antiproliferative, antiangiogenic, and anti-inflammatory properties. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CASI
CUSIPN/A
Phone240-864-2600
Debt
Debt-to-Equity Ratio0.04%
Current Ratio8.66%
Quick Ratio8.66%
Price-To-Earnings
Trailing P/E Ratio-35.89
Forward P/E Ratio-29.36
P/E GrowthN/A
Sales & Book Value
Annual Sales$50,000.00
Price / Sales11,121.54
Cash FlowN/A
Price / CashN/A
Book Value$0.55 per share
Price / Book11.75
Profitability
EPS (Most Recent Fiscal Year)($0.18)
Net Income$-10,770,000.00
Net MarginsN/A
Return on Equity-47.68%
Return on Assets-36.47%
Miscellaneous
Employees51
Outstanding Shares86,080,000
EntreMed (NASDAQ:CASI) Frequently Asked Questions
What is EntreMed's stock symbol?
EntreMed trades on the NASDAQ under the ticker symbol "CASI."
How were EntreMed's earnings last quarter?
EntreMed, Inc. (NASDAQ:CASI) released its earnings results on Thursday, March, 29th. The biotechnology company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of ($0.02) by $0.06. View EntreMed's Earnings History.
What price target have analysts set for CASI?
2 equities research analysts have issued 1 year price targets for EntreMed's shares. Their forecasts range from $4.00 to $7.00. On average, they expect EntreMed's stock price to reach $5.50 in the next twelve months. View Analyst Ratings for EntreMed.
What are Wall Street analysts saying about EntreMed stock?
Here are some recent quotes from research analysts about EntreMed stock:
- 1. HC Wainwright analysts commented, "Olga Smolentseva, Ph.D. – (646-975-6966) / [email protected] Acquisition of Sandoz Portfolio Could Lead to Commerical Launch in 12 Months; Reiterate Buy A transformative acquisition. On January 26, CASI announced the acquisition of an abbreviated new drug application (ANDA) portfolio from Sandoz, the generic drug division of Novartis (NVS; not rated), for $18M. The portfolio includes several essential medications such as Entecavir, Lisinopril, Methimazole, and Midodrine and covers a broad spectrum of drugs such as antivirals, anti-depressants, hypertension drugs, and anti-inflammatory drugs. In our view, the acquisition of these 25 approved and 4 pending ANDAs is a transformative event for the company. With the worldwide ANDA data exclusivity, CASI can now quickly become a commercial force in both China and the US." (1/29/2018)
- 2. Maxim Group analysts commented, "CASI Pharmaceuticals reported 3Q17 with a net loss of $1.6M and ended the period with $21.6M in cash. The company completed an equity financing in October, raising $23.8M. Combined, we estimate CASI currently has $44M on the balance sheet, sufficient runway into 2020. Our model has been adjusted accordingly. As we had already factored in future capital raises, the net effect is our price target of $4 remains unchanged." (11/14/2017)
Are investors shorting EntreMed?
EntreMed saw a increase in short interest during the month of April. As of April 13th, there was short interest totalling 1,871,455 shares, an increase of 33.8% from the March 30th total of 1,399,161 shares. Based on an average daily trading volume, of 2,179,588 shares, the short-interest ratio is presently 0.9 days. Approximately 9.1% of the shares of the company are short sold.
Who are some of EntreMed's key competitors?
Some companies that are related to EntreMed include CRISPR Therapeutics (CRSP), Aerie Pharmaceuticals (AERI), Denali Therapeutics (DNLI), Repligen (RGEN), Acceleron Pharma (XLRN), Editas Medicine (EDIT), Sangamo Therapeutics (SGMO), Atara Biotherapeutics (ATRA), Momenta Pharmaceuticals (MNTA), Audentes Therapeutics (BOLD), DBV Technologies (DBVT), Iovance Biotherapeutics (IOVA), Cellectis (CLLS), REGENXBIO (RGNX) and Adaptimmune Therapeutics (ADAP).
Who are EntreMed's key executives?
EntreMed's management team includes the folowing people:
- Dr. Wei-Wu He Ph.D., Exec. Chairman (Age 53)
- Dr. Ken Keyong Ren M.D., Ph.D., Chief Exec. Officer and Director (Age 59)
- Ms. Sara B. Capitelli CPA, Principal Accounting Officer and Vice-Pres of Fin. (Age 52)
- Ms. Cynthia Wong Hu J.D., Chief Operating Officer, Gen. Counsel and Sec. (Age 48)
- Dr. James E. Goldschmidt Ph.D., VP of Bus. Devel.
Has EntreMed been receiving favorable news coverage?
Press coverage about CASI stock has trended positive on Wednesday, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. EntreMed earned a media sentiment score of 0.42 on Accern's scale. They also gave media stories about the biotechnology company an impact score of 43.95 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
How do I buy shares of EntreMed?
Shares of CASI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is EntreMed's stock price today?
One share of CASI stock can currently be purchased for approximately $6.46.
How big of a company is EntreMed?
EntreMed has a market capitalization of $602.55 million and generates $50,000.00 in revenue each year. The biotechnology company earns $-10,770,000.00 in net income (profit) each year or ($0.18) on an earnings per share basis. EntreMed employs 51 workers across the globe.
How can I contact EntreMed?
EntreMed's mailing address is 9620 MEDICAL CENTER DR STE 300, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-864-2600 or via email at [email protected]
MarketBeat Community Rating for EntreMed (CASI)
MarketBeat's community ratings are surveys of what our community members think about EntreMed and other stocks. Vote "Outperform" if you believe CASI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CASI will underperform the S&P 500 over the long term. You may vote once every thirty days.
EntreMed (NASDAQ:CASI) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for EntreMed in the last 12 months. Their average twelve-month price target is $5.50, suggesting that the stock has a possible downside of 14.86%. The high price target for CASI is $7.00 and the low price target for CASI is $4.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $5.50 | $4.25 | $4.50 | $3.00 |
| Price Target Upside: | 14.86% downside | 9.82% upside | 20.00% upside | 172.73% upside |
EntreMed (NASDAQ:CASI) Consensus Price Target History
EntreMed (NASDAQ:CASI) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 4/4/2018 | HC Wainwright | Reiterated Rating | Buy | $7.00 | High |  |
| 11/14/2017 | Maxim Group | Set Price Target | Buy | $4.00 | N/A | |
(Data available from 4/25/2016 forward)
EntreMed (NASDAQ:CASI) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
EntreMed (NASDAQ CASI) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 24.66%
Institutional Ownership Percentage: 4.53%
EntreMed (NASDAQ CASI) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/21/2018 | China Growth Fund Idg-Accel II | Major Shareholder | Buy | 3,086,418 | $3.19 | $9,845,673.42 | | |
| 3/19/2018 | Wei-Wu He | Director | Buy | 3,086,419 | $3.24 | $9,999,997.56 | 847,527 | |
| 12/22/2017 | Spectrum Pharmaceuticals Inc | Major Shareholder | Buy | 1,519,096 | $0.01 | $15,190.96 | 6,897,413 | |
| 10/10/2017 | Wei-Wu He | Director | Buy | 100,000 | $1.95 | $195,000.00 | | |
| 10/6/2017 | Wei-Wu He | Director | Buy | 200,000 | $1.83 | $366,000.00 | | |
| 9/19/2017 | Wei-Wu He | Director | Buy | 207,502 | $1.75 | $363,128.50 | 513,525 | |
| 9/18/2017 | Wei-Wu He | Director | Buy | 173,500 | $1.75 | $303,625.00 | 513,525 | |
| 9/15/2017 | Wei-Wu He | Director | Buy | 315,327 | $1.33 | $419,384.91 | 212,323 | |
| 10/28/2016 | Spectrum Pharmaceuticals Inc | Major Shareholder | Buy | 1,789,062 | $0.01 | $17,890.62 | 5,695,242 | |
| 10/3/2016 | Wei-Wu He | Director | Buy | 1,871,605 | $1.19 | $2,227,209.95 | 24,698 | |
| 6/24/2016 | Byte Ltd Sparkle | Major Shareholder | Buy | 3,753,855 | $1.19 | $4,467,087.45 | | |
| 3/7/2016 | China Growth Fund Idg-Accel II | Major Shareholder | Buy | 972,708 | $2.40 | $2,334,499.20 | | |
| 1/19/2016 | Cynthia W. Hu | COO | Buy | 16,800 | $0.72 | $12,096.00 | 17,785 | |
| 1/19/2016 | Ken Ren | CEO | Buy | 15,000 | $0.73 | $10,950.00 | 15,000 | |
(Data available from 1/1/2013 forward)
EntreMed (NASDAQ CASI) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Critical Review: EntreMed (CASI) and Seattle Genetics (SGEN)
www.americanbankingnews.com - April 25 at 3:32 PM |
| -$0.07 EPS Expected for EntreMed, Inc. (CASI) This Quarter
www.americanbankingnews.com - April 24 at 7:21 PM |
| Zacks: Brokerages Expect EntreMed, Inc. (CASI) to Announce -$0.02 EPS
www.americanbankingnews.com - April 7 at 7:10 PM |
 | Here's Why CASI Pharmaceuticals Rose as Much as 23.4% Today
finance.yahoo.com - April 6 at 4:30 PM |
| CASI Pharmaceuticals Provides Update On EVOMELA®
finance.yahoo.com - April 5 at 8:49 AM |
| HC Wainwright Analysts Give EntreMed (CASI) a $7.00 Price Target
www.americanbankingnews.com - April 4 at 10:28 AM |
| BidaskClub Upgrades EntreMed (CASI) to "Buy"
www.americanbankingnews.com - April 4 at 9:31 AM |
| EntreMed (CASI) Rating Increased to Buy at ValuEngine
www.americanbankingnews.com - April 3 at 7:01 PM |
| Analysts Set $5.83 Price Target for EntreMed, Inc. (CASI)
www.americanbankingnews.com - April 1 at 1:28 AM |
| EntreMed (CASI) Announces Earnings Results
www.americanbankingnews.com - March 30 at 7:54 AM |
| CASI Pharmaceuticals Announces Fourth Quarter And Full Year 2017 Financial Results
finance.yahoo.com - March 29 at 10:05 AM |
| EntreMed (CASI) Receives "Buy" Rating from HC Wainwright
www.americanbankingnews.com - March 28 at 2:42 PM |
| Insider Buying: CASI Pharmaceuticals Inc (CASI) Major Shareholder Buys 3,086,418 Shares of Stock
www.americanbankingnews.com - March 23 at 4:32 PM |
| CASI Pharmaceuticals (CASI) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - March 22 at 1:14 AM |
| Wei-Wu He Buys 3,086,419 Shares of CASI Pharmaceuticals Inc (CASI) Stock
www.americanbankingnews.com - March 21 at 7:14 PM |
| CASI Pharmaceuticals (CASI) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - March 21 at 12:50 AM |
 | CASI Pharmaceuticals Announces $50 Million Private Placement To Prepare Company For Commercialization In China - PR Newswire (press release)
www.prnewswire.com - March 20 at 4:11 PM |
| CASI Pharmaceuticals Announces $50 Million Private Placement To Prepare Company For Commercialization In China
finance.yahoo.com - March 20 at 9:52 AM |
| CASI Pharmaceuticals (CASI) Downgraded to "Sell" at ValuEngine
www.americanbankingnews.com - March 18 at 8:16 PM |
| Analyzing Mesoblast (MESO) and CASI Pharmaceuticals (CASI)
www.americanbankingnews.com - March 5 at 9:38 AM |
| CASI Pharmaceuticals Inc (CASI) Short Interest Update
www.americanbankingnews.com - March 3 at 3:26 AM |
| BidaskClub Downgrades CASI Pharmaceuticals (CASI) to Buy
www.americanbankingnews.com - February 14 at 10:40 PM |
 | BRIEF-CASI Pharma Board Approves Appointment Of Wei-Wu He As Executive Chairman
www.reuters.com - February 9 at 5:33 PM |
| CASI Pharmaceuticals to Present at the BIO CEO & Investor Conference
finance.yahoo.com - February 9 at 9:05 AM |
| Wired News – CASI Pharma Purchased abbreviated new drug applications Portfolio from Sandoz
finance.yahoo.com - January 30 at 9:23 AM |
| CASI Pharmaceuticals (CASI) Given "Buy" Rating at HC Wainwright
www.americanbankingnews.com - January 29 at 8:22 AM |
| CASI Pharmaceuticals Acquires ANDA Portfolio From Sandoz Inc. (Sandoz)
finance.yahoo.com - January 27 at 9:21 AM |
| FY2017 EPS Estimates for CASI Pharmaceuticals, Inc. (CASI) Increased by Analyst
www.americanbankingnews.com - January 8 at 2:56 AM |
| Spectrum Pharmaceuticals Inc Buys 1,519,096 Shares of CASI Pharmaceuticals, Inc. (CASI) Stock
www.americanbankingnews.com - December 22 at 6:14 PM |
| Free Research Reports on these Biotech Stocks -- Vericel, ZIOPHARM Oncology, Cerecor, and CASI Pharma - PR Newswire (press release)
www.prnewswire.com - December 19 at 4:58 PM |
 | Mid-Morning Market Update: Markets Open Higher; VeriFone Issues Weak Outlook - Nasdaq
www.nasdaq.com - December 13 at 5:09 PM |
| CASI Pharmaceuticals Announces Poster Presentation At The 2017 San Antonio Breast Cancer SymposiumTM (SABCS) On ENMD-2076 In Patients With Triple-Negative Breast Cancer (TNBC)
finance.yahoo.com - December 1 at 5:10 PM |
| CASI Pharmaceuticals, Inc. (CASI) Given $3.50 Consensus Price Target by Brokerages
www.americanbankingnews.com - November 23 at 1:28 PM |
| CASI Pharmaceuticals, Inc. (CASI) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - November 15 at 1:05 PM |
| CASI Pharmaceuticals Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 14 at 5:27 PM |
| CASI Pharmaceuticals' (CASI) Buy Rating Reiterated at Maxim Group
www.americanbankingnews.com - November 14 at 4:40 PM |
| CASI Pharmaceuticals, Inc. (CASI) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - November 6 at 5:22 AM |
| CASI Pharmaceuticals (CASI) vs. Brainstorm Cell Therapeutics (BCLI) Head to Head Comparison
www.americanbankingnews.com - November 5 at 9:12 PM |
| -$0.04 EPS Expected for CASI Pharmaceuticals, Inc. (CASI) This Quarter
www.americanbankingnews.com - November 1 at 9:16 PM |
| Analyzing CASI Pharmaceuticals (CASI) and Adamas Pharmaceuticals (ADMS)
www.americanbankingnews.com - November 1 at 5:12 PM |
| CASI Pharmaceuticals, Capital Raise, Analysts Review, Product Development, and Guidance
finance.yahoo.com - October 31 at 6:07 PM |
| Reviewing CASI Pharmaceuticals (CASI) & The Competition
www.americanbankingnews.com - October 21 at 2:24 AM |
 | CASI Pharma (CASI) Announces 7.95M Share Registed Direct Offering at $3/Sh
www.streetinsider.com - October 14 at 4:43 PM |
| CASI Pharmaceuticals Announces $23.8 Million Registered Direct Offering Led By Existing Shareholders - PR Newswire (press release)
www.prnewswire.com - October 14 at 3:37 AM |
 | CASI Pharmaceuticals Reaches Analyst Target Price
www.thestreet.com - October 13 at 5:37 PM |
| CASI Pharmaceuticals Announces $23.8 Million Registered Direct Offering Led By Existing Shareholders
finance.yahoo.com - October 13 at 5:37 PM |
| Insider Buying: CASI Pharmaceuticals, Inc. (CASI) Director Purchases 100,000 Shares of Stock
www.americanbankingnews.com - October 11 at 7:50 PM |
| CASI Pharmaceuticals, Inc. (CASI) Director Acquires $366,000.00 in Stock
www.americanbankingnews.com - October 10 at 7:38 PM |
| Head-To-Head Review: CASI Pharmaceuticals (CASI) & Its Rivals
www.americanbankingnews.com - September 25 at 2:20 AM |
| CASI Pharmaceuticals, Inc. (CASI) Expected to Announce Earnings of -$0.04 Per Share
www.americanbankingnews.com - September 25 at 2:16 AM |
EntreMed (NASDAQ:CASI) SEC Filings
This page is loading this company's SEC Filings. Please wait...
EntreMed (NASDAQ:CASI) Income Statement, Balance Sheet and Cash Flow Statement
EntreMed (NASDAQ CASI) Stock Chart for Wednesday, April, 25, 2018
Loading chart…
